CIK 0001743881
- Large accelerated filer
BridgeBio Pharma, Inc.
Sign in to watch- Ticker
- BBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 650-391-9740
- Business address
- 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
- Former names
- BridgeBio Pharma LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,117,307
- in 3 filings, $5.1M under 10b5-1 plans
Net −$5,117,307. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-03 | Stolz Brian M. Chief Operating Officer | Grant or award · Restricted Stock Units | +25,532 | 25,532 | ||
| 2020-06-03 | Kumar Neil CEO and President | Sale | −5,930 | $30.05 | $178K | 2,319,442 |
| 2020-06-03 | Kumar Neil CEO and President | Grant or award · Stock Option (Right to Buy) | +590,551 | 590,551 | ||
| 2020-06-03 | Kumar Neil CEO and President | Grant or award · Restricted Stock Units | +82,069 | 82,069 | ||
| 2020-06-02 | Cook Jennifer E. Director | Grant or award · Stock Option (right to buy) | +112,422 | 112,422 | ||
| 2020-06-02 | HOMCY CHARLES J Chairman of Pharmaceuticals | Grant or award · Stock Option (right to buy) | +112,422 | 112,422 | ||
| 2020-06-02 | MOMTAZEE JAMES C Director | Grant or award · Stock Option (right to buy) | +112,422 | 112,422 | ||
| 2020-06-02 | Satvat Ali J. Director | Grant or award · Stock Option (right to buy) | +112,422 | 112,422 | ||
| 2020-06-02 | SCHELLER RICHARD H Director | Grant or award · Stock Option (right to buy) | +112,422 | 112,422 | ||
| 2020-06-02 | AGUIAR ERIC Director | Grant or award · Stock Option (right to buy) | +112,422 | 112,422 | ||
| 2020-06-01 | Sinha Uma Chief Scientific Officer | Grant or award · Restricted Stock Units | +7,500 | 7,500 | ||
| 2020-06-01 | Kumar Neil CEO and President | Sale | −71,291 | $29.13 | $2.1M | 2,334,081 |
| 2020-06-01 | Kumar Neil CEO and President | Sale | −8,709 | $29.71 | $259K | 2,325,372 |
| 2020-06-01 | STEPHENSON BRIAN C | Sale | −6,300 | $29.31 | $185K | 309,616 |
| 2020-06-01 | STEPHENSON BRIAN C | Sale | −900 | $29.74 | $27K | 308,716 |
| 2020-06-01 | HENDERSON MICHAEL THOMAS Chief Business Officer | Sale | −2,085 | $29.26 | $61K | 262,183 |
| 2020-06-01 | HENDERSON MICHAEL THOMAS Chief Business Officer | Sale | −500 | $29.79 | $15K | 261,683 |
| 2020-05-28 | KKR Genetic Disorder L.P. 10% owner | Sale | −2,389,690 | $33.39 | $79.8M | 34,510,971 |
| 2020-05-26 | HENDERSON MICHAEL THOMAS Chief Business Officer | Exercise or conversion | +18,365 | $1.05 | $19K | 264,268 |
| 2020-05-26 | HENDERSON MICHAEL THOMAS Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) | −18,365 | 0 |
Page 50 of 61 · 1,201 trades